Recipient: University of Munich Hospital
Funding: Go-Bio initial (01/10/2022 to 30/09/2023, EUR 119,999.76)

Project description:

On average only four out of ten tumours in the metastatic stage respond to the respective cancer therapy. The individual cultivation of cancer cells (tumoroids) enables the testing of potential pharmaceuticals and the screening of new effective therapeutics that are tailored to the patient.

The aim of the project is to develop a platform for individual drug testing that enables recommendations for treatment with the most effective drugs against an individual tumour. Thus, after the initial treatment with the standard therapy, the therapy could be switched without loss of time. Tumoroids can further be used for testing drug candidates in the pharmaceutical industry.

During the course of preparatory work, the "High-Yield-Complete-Spectrum" (HYCS) platform could be continuously optimised in such a way that, for the first time, the complete tumoroid spectrum can be reliably cultivated. In this way the project can be focused and further exploitation steps can be prepared.